Commissariat &#xc0; L'&#xc9;nergie Atomique Et Aux &#xc9;nergies Alternatives

Centre National De La Recherche Scientifique

Institut Curie

The University of Texas System

Institut Pasteur

Centre Nationale De La Recherche Scientifique

Centre National De La Recherche Scientifique-cnrs

Julien Barbier

Daniel Gillet

Jean-Christophe Cintrat

Ludger Johannes

Thomas Rudel

Jo-Ana Herweg

Annette Fischer

Siau-Kun Bai

Bahne Stechmann

Romain Noel

Philippe Brulet

Robert A Davey

Jordi Molgo

Karen Hinsinger

Valérie Pons

Sylvie Roux

Cécile Saint Cloment

Hajer Abdelkafi

Alain Pruvost

Audrey Couhert

Robin Vinck

Livia Tepshi

Cécile Institut Pasteur Saint Cloment

The invention relates to a new family of compounds of the type 2,3-dihydroquinazolin-4(1H)-one and the use thereof as inhibitors of the toxic effects of intracellular-acting toxins, such as ricin, Shiga toxins or the cholera toxin, using retrograde transport to intoxicate the cells, or viruses or bacteria using retrograde and/or syntaxin 5-dependent transport to infect the cells, specifically viruses or bacteria entering into the cells by means of endocytosis, or intracellular parasites.

Dihydroquinazolinones exhibiting protective activity against intracellular-acting toxins, intracellular viruses and bacteria

The invention relates to a method for treating a Chlamidyales infection comprising the administration of a therapeutically effective amount of a compound of formula (I) to a subject in need thereof: Wherein R, R, Rand Ar are as defined in claim

Benzodiazepine derivatives for use in the treatment of Chlamydiales infections

The present invention relates to a method for treating a Chlamydiales infection comprising the administration of a therapeutically effective amount of a compound of formula (I) to a subject in need thereof:W-L-NH-L-Ar&#x2003;&#x2003; (I)Wherein W, L1, L2 and Ar are as defined in claim

Adamantane or pinene derivatives for use in the treatment of chlamydiales infections

Use of 2,3-dihydroquinazolin-4(1H)-one cyclic derivatives of formula (I) for the treatment of infection with viruses entering cells by endocytosis, especially filovirus such as Ebolavirus. 

2,3-dihydroquinazolin-4(1H)-one derivatives for use in the treatment of viral infections

The present invention relates to a method for treating a Chlamydiae infection comprising the administration of a therapeutically effective amount of a compound of formula (I) to a subject in need thereof: Wherein, R1, R2, R3, R4 and p are as defined in claim

Quinazolinone derivatives for use in the treatment of chlamydiales infections

The present invention concerns a new family of 2,3-dihydroquinazolin-4(1H)-one compounds of general formula (I), and the use thereof as inhibitors of the toxic effects of toxins with intracellular activity, such as ricin or Shiga toxin, for example, using retrograde transport to intoxicate cells.

Compounds having a protective activity against toxins with intracellular activity

The present invention relates to the use of compounds of general formula (I) and (II) for the preparation of a drug for preventing and/or treating disorders caused by Shiga toxins and related toxins.

Inhibitors of the shiga toxins trafficking through the retrograde pathway

Inhibitors of the Shiga toxins trafficking through the retrograde pathway

A hybrid protein (GFP-TTC) comprising the non-toxic proteolytic C fragment of tetanus toxin fused to green fluorescent protein was used to analyze the functional synaptic organization of neural networks. When injected intramuscularly in vivo, the GFP-TTC hybrid protein binds to tetanus neurotoxin receptors and clusters very rapidly to the active neuromuscular junction. Membrane traffic by GFP-TTC at the pre-synaptic level of the neuromuscular junction is strongly and rapidly influenced by exogenously co-injecting neurotrophic factors, such as BDNF, NT-4, and GDNF, but not by NGF, NT-3, and CNTF. The membrane traffic, directly detected using GFP-TTC in vivo, permits methods of analyzing synaptic functioning as well as methods of modulating neuronal transport using neurotrophic factors and agonists or antagonists thereof.

In vivo modulation of neuronal transport

Growing community of inventors

Gif-sur-Yvette, France

Julien Barbier